Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer
| Autor: | J Dethling, R. Lorenz, U. Seifart, K Hans, T Fink, M. Wolf, Carmen Schade-Brittinger, G. Koschel, H. Schroeder, C. Mueller |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Lung Neoplasms Time Factors Adolescent Maximum Tolerated Dose endocrine system diseases medicine.medical_treatment Urology Phases of clinical research Bone Neoplasms Central Nervous System Neoplasms chemistry.chemical_compound Antineoplastic Combined Chemotherapy Protocols medicine Humans Carcinoma Small Cell Infusions Intravenous Lung cancer Survival rate Aged Cisplatin Chemotherapy business.industry Liver Neoplasms Hematology Middle Aged medicine.disease Carboplatin Surgery Survival Rate Regimen Treatment Outcome Oncology chemistry Female Topotecan business medicine.drug |
| Zdroj: | Annals of Oncology. 18:104-109 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdl353 |
| Popis: | Background: Topotecan is an active drug in small-cell lung cancer (SCLC). In our previous study, a combination of topotecan with cisplatin was associated with a median overall survival of 7.6 or 8.7 months, depending on the duration of treatment. We have replaced cisplatin by carboplatin in this trial, with the objective of creating a more convenient schedule for our patients. Furthermore, we have also compared the standard 5-day schedule with an experimental 3-day schedule. Patients and methods: A total of 100 patients with metastatic disease were included. Patients were randomly assigned to receive either topotecan 0.75 mg/m2, days 1–5, and carboplatin AUC 5, day 5 (arm A) or topotecan 1.25 mg/m2, days 1–3, and carboplatin AUC 5, day 3 (arm B). Six cycles were given at a 3-week interval. Results: A total of 91 patients were assessable for response. The response during therapy was 86.9% in arm A and 80.0% in arm B. Median survival in arm A was 11.8 months and in arm B 11.6 months (P = 0.37). Conclusions: The combination of topotecan and carboplatin is active in extensive-disease SCLC. Toxicity and median survival were comparable in both arms. Three days of treatment seems to be similar to the 5-day regimen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|